Cytrellis Biosystems, Inc. Company Profile

Background

Cytrellis Biosystems, Inc., founded in 2015 and headquartered in Woburn, Massachusetts, is a medical technology company dedicated to developing and commercializing first-in-class aesthetic devices. The company's mission is to revolutionize the aesthetics industry by providing innovative, minimally invasive solutions that address the visible signs of aging. Cytrellis' flagship product, the ellacor® system with Micro-Coring® technology, exemplifies this commitment by offering a novel approach to skin rejuvenation without the need for surgery or thermal energy.

Key Strategic Focus

Cytrellis focuses on advancing aesthetic medical technology through the development of proprietary devices that enable the removal of sagging skin and treatment of wrinkles in a minimally invasive manner. The company's core objectives include enhancing patient outcomes, reducing procedure times, and improving the overall patient and provider experience. The ellacor® system, utilizing Micro-Coring® technology, targets moderate to severe wrinkles in the mid and lower face, providing a non-surgical alternative for skin rejuvenation.

Financials and Funding

In September 2021, Cytrellis completed a $50 million Series C financing round led by D1 Capital Partners, with participation from Sands Capital, ARCH Venture Partners, and PFM Health Sciences. The funds were allocated to develop the company's commercial infrastructure, support additional clinical research, product development, and manufacturing.

Pipeline Development

The ellacor® system with Micro-Coring® technology is Cytrellis' primary product, having received FDA clearance in 2021 for the treatment of moderate to severe wrinkles in the mid to lower face. Following its initial limited release in 2022, the company launched ellacor® 2.0 in January 2025, incorporating enhancements such as a 35% reduction in procedure time and improved patient outcomes, including a 60% decrease in healing time. Cytrellis continues to explore new indications and markets for the ellacor® system, with recent approvals from Health Canada and the Saudi Food and Drug Authority in March 2025.

Technological Platform and Innovation

Cytrellis' proprietary Micro-Coring® technology sets it apart in the aesthetic medical device industry. This innovative approach involves the use of hollow needles to remove micro-cores of dermal and epidermal tissue, facilitating skin rejuvenation without surgery, thermal energy, or scarring. The technology stimulates the body's natural healing process, resulting in improved skin appearance and reduced wrinkles.

Leadership Team

Dr. Denise Dajles, President & CEO: Appointed in January 2025, Dr. Dajles brings over 20 years of experience in medical device innovation, operations, and regulatory affairs. Prior to joining Cytrellis, she served as Chief Technical Officer at Sientra and held leadership roles at Establishment Labs. Dr. Dajles holds a Doctor of Engineering from George Washington University and MS and BS degrees in Biomedical Engineering from Washington University.

Bob Hinz, VP Operations: With extensive experience in operations and service leadership, Mr. Hinz previously served as VP of Operations at Medica Corporation and held leadership roles at Koch Membrane Systems. He is a U.S. Navy veteran and holds an MBA in Technology Management.

Dr. Karyn Siemasko, VP Medical Affairs: Dr. Siemasko has over 20 years of experience in medical affairs and scientific strategy, including senior leadership roles at Merz Aesthetics, Santen, Kythera, and Allergan. She holds a Ph.D. in Immunology from Rush University and completed a postdoctoral fellowship at the University of Chicago.

Sarah Brice, RN, BSN, VP Commercial Strategy: Ms. Brice brings 15 years of leadership experience in medical device sales and marketing, with roles at GAINSWave, Cutera, and MPMG Brands. She is a registered nurse with a BSN from the University of Oklahoma.

Oliver Bennett, Chief Business Officer and General Counsel: Mr. Bennett has over 20 years of experience in driving profitable growth through organic and inorganic pathways. He previously served as Chief Legal, Compliance, and Corporate Development Officer at Sientra, Inc. He holds a bachelor's degree and law degree from Griffith University in Australia and an LLM from Harvard Law School.

Leadership Changes

In January 2025, Dr. Denise Dajles was appointed as President and CEO, succeeding Karen Cronholm. Additionally, in June 2025, Cytrellis strengthened its leadership team with the appointments of Dr. Karyn Siemasko as VP of Clinical and Medical Affairs, Sarah Brice as VP of Commercial Strategy, and Oliver Bennett as Chief Business Officer and General Counsel.

Competitor Profile

Market Insights and Dynamics

The global medical aesthetics market is experiencing significant growth, driven by increasing demand for minimally invasive procedures and advancements in technology. Cytrellis operates within this dynamic landscape, focusing on innovative solutions for skin rejuvenation.

Competitor Analysis

Cytrellis faces competition from several established companies in the aesthetic medical device industry:

ZELTIQ Aesthetics (CoolSculpting): Specializes in non-invasive fat reduction procedures.

7E Wellness: Provides non-invasive technology for skin and body care.

Candela Medical: Offers a range of medical aesthetic devices.

SkinStylus: Distributes skincare laser microneedling devices.

These competitors offer various technologies and treatments, positioning themselves in the non-invasive aesthetic procedures market.

Strategic Collaborations and Partnerships

Cytrellis collaborates with leading dermatologists and plastic surgeons to develop and refine its products. The company's scientific founders, Dr. Rox Anderson and Dr. William G. Austen, Jr., are prominent figures in the field, contributing to the innovation and credibility of Cytrellis' offerings.

Operational Insights

Cytrellis differentiates itself through its proprietary Micro-Coring® technology, offering a unique, minimally invasive solution for skin rejuvenation. The company's focus on continuous product improvement, as demonstrated by the launch of ellacor® 2.0, and strategic leadership appointments position it to effectively compete in the growing aesthetic medical device market.

Strategic Opportunities and Future Directions

With recent regulatory approvals in Canada and Saudi Arabia, Cytrellis is poised for international expansion. The company continues to invest in clinical research and product development, exploring new indications and markets for the ellacor® system. Strategic leadership appointments and a commitment to innovation position Cytrellis to capitalize on emerging opportunities in the aesthetic medical device industry.